Euclises Pharmaceuticals, Inc. is a drug discovery and development company advancing the next generation of oral, small-molecule drugs that target COX-2 to disrupt the tumor microenvironment and kill cancer cells. Blocking this key target has been shown to (a) slow tumor growth, (b) augment the activity of immune checkpoint inhibitors by eliminating COX-2/PGE-2 mediated tumor immune evasion, and (c) boost the efficacy of other targeted agents such as EGFR inhibitors by shutting down resistance pathways.
Our mission is to advance these new molecules in combinations with both immune checkpoint and EGFR inhibitors through initial clinical trials.
We believe this approach has the potential to dramatically improve the overall efficacy of current immuno-oncology therapies and EGFR inhibitors, and to expand the number of patients who benefit from these agents.
Euclises boasts a team of pharmaceutical veterans who have led development of dozens of clinical candidates and marketed drugs.